Oncosome Formation in Prostate Cancer: Association with a Region of Frequent Chromosomal Deletion in Metastatic Disease

Doñel Di Vizio,1,2 Jayoung Kim,1,2 Martin H. Hager,1,2 Matteo Morello,1,2 Wei Yang,1,2 Christopher J. Lafargue,1 Lawrence D. True,1 Mark A. Rubin,1 Rosalyn M. Adam,1,2 Rameen Beroukhim,4,5,6 Francesca Demichelis,7,8, and Michael R. Freeman1,2,3

The Urological Diseases Research Center, Children's Hospital Boston; Departments of Surgery and Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Department of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute; and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Pathology, University of Washington Medical Center, Seattle, Washington; Department of Pathology and Laboratory Medicine and Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York; and Broad Institute of MIT and Harvard, Cambridge, Massachusetts

Abstract

Oncosomes have recently been described as membrane-derived microvesicles secreted by cancer cells, which transfer oncogenic signals and protein complexes across cell boundaries. Here, we show the rapid formation and secretion of oncosomes from DU145 and LNCaP human prostate cancer cells. Oncosome formation was stimulated by epidermal growth factor receptor activation and also by overexpression of membrane-targeted Akt1. Microvesicles shed from prostate cancer cells contained numerous signal transduction proteins and were capable of activating rapid phospho-tyrosine and Akt pathway signaling, and stimulating proliferation and migration, in recipient tumor cells. They also induced a stromal reaction in recipient normal cells. Knockdown of the actin nucleating protein Diaphanous Related Formin 3 (DRF3/Dia2) by RNA interference enhanced rates of oncosome formation, indicating that these structures resemble, and may be identical to, nonapoptotic membrane blebs, a feature of the amoeboid form of cell motility. Analysis of primary and metastatic human prostate tumors using 100K single nucleotide polymorphism arrays revealed a significantly higher frequency of deletion of the locus encoding DRF3 (DIAPH3) in metastatic tumors (P = 0.001) in comparison with organ-confined tumors. Fluorescence in situ hybridization confirmed increased chromosomal loss of DIAPH3 in metastatic tumors in a different cohort of patients (P = 0.006). These data suggest that microvesicles shed from prostate cancer cells can alter the tumor microenvironment in a manner that may promote disease progression. They also show that DRF3 is a physiologically relevant protein that seems to regulate this process. [Cancer Res 2009;69(13):5601–9]

Introduction

Prostate cancer (PCa) is a major cause of cancer-related death in Western countries. Although the majority of cancers are unlikely to progress to end-stage disease, castration-resistant PCa is still a major clinical challenge. The development of effective therapies for advanced PCa requires an understanding of the processes that promote the metastatic state. Cancer cells colonize distant sites using several strategies, including production of proteases that degrade extracellular matrix (1), and extension of lamellipodia, filopodia, and other dynamic cell processes that mediate migration (2). Formation of lamellipodia, which generate force at the front end of a migrating cell, requires actin filament assembly and the coordinated activity of multiple protein complexes that regulate assembly and disassembly of the cytoskeleton (3).

A less studied mode of cell motility, termed “amoeboid” movement, occurs as a result of nonapoptotic blebbing (4, 5). Plasma membrane blebs arise from actomyosin contractions near the cortical cytoskeleton, which create the opportunity for rapidly forming membrane protrusions to arise from hydrostatic pressure. Actin filament assembly is not required for the formation of nonapoptotic blebs, but force generated by actin filaments is required for bleb retraction. Bleb-associated movement is mediated by Rho-GTPase/ROCK signaling (6) and generates propulsive motion through a three-dimensional matrix in a manner that requires limited or no proteolysis (7). The mechanisms that control the amoeboid phenotype in tumor cells are poorly understood, as is the role of this process in malignant progression.

Oncosomes are recently discovered membranous microvesicles that have been implicated in rapid intercellular transfer of oncogenic information from glioblastoma to indolent glioma cells (8). Although this process resembles paracrine signaling, it involves intercellular transfer of a membrane-bound micro-organelle rather than a soluble protein such as a growth factor or cytokine. In the present study, we show that PCa cells shed membrane-bound vesicles in response to signal transducers. These structures are of large (0.5 to ~5 μm), originate from nonapoptotic blebs in response to signaling cues, and have biological activity in their free-floating state. We also identify the formin homology protein, DRF3/Dia2, as a protein that seems to functionally inhibit oncosome formation. We also provide the first evidence that chromosomal loss at the DRF3 locus (DIAPH3) is associated with metastatic PCa.

Materials and Methods

Reagents. Antibodies were from Biosource, Cell Signaling, BD Transduction, Santa Cruz Biotechnologies, Sigma, Covance, Inc., and Upstate. ZD1839 (gefitinib) was from AstraZeneca. FuGENE6 was from Roche. Other reagents were from Sigma. Anti-DRF3 monoclonal antibody was a gift from Dr. H. Higgs (Dartmouth Medical School, Hanover, NH).
Cell culture and transfections. DU145, LNCaP, and WPMY-1 cell lines were from the American Type Culture Collection. hTERT-immortalized normal prostate epithelial cells (iPrEC), generously provided by Dr. W. Hahn (Dana-Farber Cancer Institute, Boston, MA) were kept in PrEGM medium. Stable transfectant cell populations (MyrAkt1, LacZ, HB-EGF, and Vo) were described (9, 10). Transient transfection [Cav-1-GFP (11) or pMEM-YFP (12)] were done using FuGENE6. These constructs were generously provided by Dr. M. Lisanti (Thomas Jefferson University, Philadelphia, PA) and Dr. D. Clapham (Harvard Medical School, Boston, MA), respectively.

Immunofluorescence microscopy. Cell membranes were labeled with FITC-conjugated cholera toxin B (CTxB) subunit (Sigma) or Alexa 594-conjugated CTxB (Molecular Probes) and analyzed as previously described (13).

Isolation of oncosomes and oncosome transfer assays. Shed microvesicles were collected from conditioned medium and purified essentially as described (8). Briefly, medium was subjected to two successive, rapid centrifugations at 300 and 12,000 g to eliminate cells and debris. Microvesicles were then pelleted by ultracentrifugation for 2 h at 100,000 g. Recovered material was resuspended in ice-cold PBS and quantified by measuring protein content. Recipient cells were serum-starved for 12 h and were subsequently treated with 20 μg of ultracentrifuged material.

Silencing of DRF3 expression. DU145 cells were transfected with ON-TARGETplus SMARTpool siRNA duplexes for the target sequence NM_030932, or with control nontargeting siRNA (Dharmacon, Inc.) using DharmaFECT1 reagent, for 72 h. Reverse transcription-PCR (RT-PCR) and Western Blotting were used to validate specific silencing of DRF3 expression. DIAPH3 gene–specific primer pair (5'-TATATAGGTACCGCCACCATGGACCGGCCACCCGCGGC-3' / 5'-AAGTTGGATATCCAGGCCATC-3') was used for the RT-PCR, and PCR products analyzed by agarose gel electrophoresis.

Mass spectrometry and label-free quantification. SDS-PAGE gel slices were subjected to in-gel digestion as described (14). Tryptic peptides were separated at circa 400 nL/min with 60 min linear gradients from 5% to 31% acetonitrile in 0.4% formic acid and analyzed using an LTQ ProteomeX ion trap mass spectrometer (Thermo Finnigan). Database searches were done as described (13) except that mass tolerance was set at 1.5 Da for MS/MS spectra. Proteins were identified with at least two unique peptides, with each peptide having an ion score no less than 40 (P < 0.05). Relative protein abundance was determined using label-free spectral counting (15).

Pathway enrichment and network analysis. The integrated software suite MetaCore (GeneGo) was used to map proteins into biological networks of human protein-protein, protein-DNA, and protein-compound interactions, metabolic and signaling pathways. For network analysis, two algorithms used were as follows: (a) the direct interaction algorithm to map direct protein-protein interaction; (b) the shortest path algorithm to map the shortest interaction pathway.

Figure 1. EGF induces formation of nonapoptotic membrane blebs. A, membrane staining with 0.5 μg/mL FITC-CTxB for 5 min, after 3 h of treatment with: (−) vehicle or (+) EGF (50 ng/mL), and imaged by confocal microscopy (×63). All show DU145 cells, except at the top right, which shows a PC-3 cell and SV into the medium. Inset, a single, attached bleb at higher power. B, frames (5-s interval) from Movies 1 and 2 acquired by real-time confocal microscopy of DU145 cells expressing membrane-targeted PMEM-YFP, and treated with EGF. Two examples (differently shaped arrows) of bleb dynamics. C, lysates from whole cells and SV contain endogenous Cav-1, consistent with localization of a Cav-1-GFP fusion to membrane blebs. D, EGF does not induce apoptosis under these experimental conditions, as shown by an assay for cleaved PARP.
Cell proliferation and migration assays. Cell proliferation was determined by viability assay (10). Cell migration was assessed using (a) in vitro wound healing assay and (b) cell migration chambers (Chemicon International, Inc.).

Single nucleotide polymorphism arrays. Human specimen collection and preparation have been described (16). Genomic DNA was hybridized to 100K SNP arrays (Affymetrix) according to the manufacturer’s instructions. Arrays were scanned with a GeneChip Scanner 3000, and genotyping was done using Affymetrix Genotyping Tools Version 2.0. Probe-level signal intensities were normalized to a baseline array using invariant set normalization (17). Single nucleotide polymorphism (SNP)-level signal intensities were obtained using a model-based (PM/MM) method (17). Tumor data were normalized against data from normal tissue samples selected for similar baseline noise characteristics (18). Noise was further reduced using the segmentation algorithm Gain and Loss Analysis of DNA (19). Histogram analysis (18) was used to confirm that all tumors were sufficiently enriched to observe copy-number changes. Deletion at the DIAPH3 locus was identified as segmented log2 ratio of < −0.1, a value reached in only 0.5% of SNPs in data from normal tissue.

Dual color fluorescence in situ hybridization. DIAPH3 gene alteration was assessed by fluorescence in situ hybridization (FISH) on tissue microarray sections with tissue samples from radical prostatectomy and a PCA progression tissue microarray (20). For the DIAPH3 target probe, spanning the DIAPH3 locus (chr13q21.2), the Biotin-14-dCTP–labeled BAC clones RP11-638B12 and RP11-628B12 (eventually conjugated to produce a red signal) were applied. For the reference probe, used to evaluate tumor cell ploidy on a stable area of chromosome 21, the Digoxigenin-11-dUTP–labeled BAC clone RP11-451M12 (eventually conjugated to produce a green signal) was applied. The BAC clones were from the BACPAC Resource Center, Children’s Hospital Oakland Research Institute. Correct chromosomal probe localization was confirmed on normal lymphocytes metaphase preparations. Tissue hybridization, washing, and color detection were done as described (21). The samples were analyzed under a ×60 oil immersion objective using an Olympus BX-511 fluorescence microscope, a charge-coupled device camera, and the CytoVision FISH software (Applied Imaging). Semiquantitative evaluation of the tests was done by D.D.V. and C.J.L. on at least 50 nuclei.

Results

Inducible formation of nonapoptotic blebs in PCa cells. In experiments where DU145 human PCa cells were stimulated with epidermal growth factor (EGF), we noted extensive membrane blebbing (Fig. 1), which occurred immediately (~5 minutes) following growth factor treatment and persisted for 24 hours (Supplementary Fig. S1). Newly formed blebs were predominantly 0.5 to 5 μm in diameter and could be labeled with the ganglioside probe CTxB (Fig. 1A), a membrane-directed yellow fluorescent protein (pMEM-YFP; Fig. 1B; ref. 12) or the plasma membrane glycoprotein probe wheat germ agglutinin (data not shown). Sporadic bleb formation was also observed in vehicle-treated cells. Blebbing did not coincide with increased rates of cell death (Fig. 1D), indicating that these structures are nonapoptotic membrane blebs described in other cell types (22–26) but not to our knowledge in prostatic cells. Similar rapid blebbing was evoked from the PC-3 human PCA cell line in response to EGF (Fig. 1A).

Live confocal imaging of DU145 cells expressing pMEM-YFP and treated with EGF showed blebs emerging rapidly as protrusions,

![Figure 2](https://www.aacrjournals.org/doi/fig/10.1158/0008-5472.CAN-08-3860)

**Figure 2.** Blebbing is associated with cell migration and activation of signaling, and results in production of SVs that contain membrane proteins. A, bleb formation in DU145 cells treated with EGF (50 ng/mL; 12 h) in a wound-healing assay. B, i, Bleb formation in DU145 cells treated with EGF or EGF plus gefitinib (ZD1839; 10 μmol/L). ii, bleb formation in prostate normal epithelial (iPrEC) and stromal (WPMY-1) cells, in comparison with DU145, with and without EGF, iPrEC were kept in PR/EGM medium, which is serum free but contains EGF, whereas iPrEC were transferred to serum-free RPMI 12 h before treatment. C, bleb formation in LNCaP cells stably engineered to express MyrAkt, pro-HB-EGF, or soluble (constitutively secreted) sHB-EGF. LacZ (Irrelevant gene) and pCMV (vector only) are negative controls. D, protein from whole cell lysates and SV from EGF-treated LNCaP/MyrAkt1 cells were blotted with the indicated antibodies.
which were sometimes retracted (Movie 1; Fig. 1B). Blebs were also completely extruded from the cell body and released into the medium (Movie 2; Fig. 1A and C). Isolation of shed vesicles (SV) by collection of media and ultracentrifugation indicated that they contained the membrane protein caveolin-1 (Cav-1; Fig. 1D), a PCa serum biomarker and an indicator of advanced disease (27). Consistent with this observation, blebs could also be decorated with Cav-1-GFP (Fig. 1D). An in vitro wound-healing assay showed that rates of bleb formation correlated with increased cell migration (Fig. 2A). The increase in rates of blebbing in response to EGF was completely suppressed by the EGFR inhibitor gefitinib (Fig. 2Bi).

We observed spontaneous blebbing in LNCaP PCa cells; however, basal rates of bleb formation were lower in LNCaP than in DU145, a more aggressive cell line. To determine whether blebbing would increase in response to activation of oncogenic signaling, we assessed the extent of bleb formation in LNCaP cells stably expressing the potent membrane–directed oncoprotein MyrAkt1 (9), the membrane-associated precursor form of the EGFR ligand HB-EGF (proHB-EGF), or a soluble form of HB-EGF (sHB-EGF) that is released constitutively into the medium (10). Blebbing was significantly increased in LNCaP cells expressing either proHB-EGF or sHB-EGF in the absence of exogenous EGF (Fig. 2C). Addition of EGF further increased blebbing in MyrAkt1- and proHB-EGF–expressing cells (Fig. 2C). Consistent with their sustained export of high levels of sHB-EGF, EGF did not have a further stimulatory effect on LNCaP/sHB-EGF cells. Bleb formation in normal prostate epithelial and stromal cells was modest and unresponsive to EGF (Fig. 2Bi); however, in this case, blebbing was not a reflection of EGFR level or sensitivity to ligand (Supplementary Fig. S1B).

**Bleb secretions contain numerous signal transduction proteins.** Because secreted vesicles (SV) contained Cav-1, we hypothesized that they might contain other signaling proteins as cargo. SV from LNCaP/MyrAkt1 and LNCaP cells transfected with an irrelevant gene (LacZ) were isolated by collection of medium, followed by ultracentrifugation. SV contained the membrane-associated proteins Akt and Src (Fig. 2D); however, we did not detect the largely nuclear androgen receptor and the predominantly cytosolic enzyme fatty acid synthase, both of which are expressed at high levels in LNCaP cells. We detected HA-tagged MyrAkt1 in SV from LNCaP/MyrAkt1 cells (Fig. 2D); however, LNCaP/LacZ cells also produced SV that contained endogenous Akt1 (Supplementary Fig. S2A).

![Figure 3](image-url)

**Figure 3.** SVs exhibit oncosome activity. **A,** proteins identified by tandem mass spectrometry in bleb material and quantified using spectral counting. **PDCD6IP,** Programmed Cell Death 6 Interacting Protein; **PABPC1,** Poly(A) Binding Protein, Cytoplasmic 1; **HSPA8,** Heat Shock 70 kDa Protein 8; **ANXA6,** Annexin A 6; **hnRNPK,** Heterogeneous Nuclear Ribonucleoprotein K; **PKM2,** Pyruvate Kinase M2; **PACSIN2,** Protein Kinase C and Casein Kinase Substrate in Neurons 2; **PABPC4,** Poly(A) Binding Protein, Cytoplasmic 4; **RPLO,** Ribosomal Protein Large Po-like Protein; **IGSF8,** Immunoglobulin Superfamily, member 8; **YWHAE,** Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase Activation Protein, 2 Polypeptide; **HSPA1L,** Heat Shock 70 kDa Protein 1-Like; **RPL7,** Ribosomal Protein L7; **HSPA1A,** Heat Shock 70 kDa protein 1A; **S100A7,** S100 calcium binding protein A7; **JUP,** Junction Plakoglobin; **XRCC6,** X-ray Repair Complementing defective repair in Chinese hamster cells 6. **B,** LNCaP/LacZ cells were exposed to SV obtained from EGF-treated LNCaP/MyrAkt1 cells. Blotting of whole cell lysates is shown. **C,** LNCaP/LacZ exposed to 20 μg of SV or vehicle from EGF-treated LNCaP/MyrAkt1 cells and assessed for p-Tyr (top). Bottom, the results of blotting with p-EGFR antibody (p-Tyr1068). **D,** WPMY-1 cells were exposed to LNCaP/MyrAkt1-derived SV for the indicated times. Vimentin mRNA was quantified by qRT-PCR in recipient cells, and normalized using GAPDH. An irrelevant gene, **PRKAR1A,** was used as control.

Cancer Res 2009; 69: (13). July 1, 2009 5604 www.aacrjournals.org

Published OnlineFirst June 23, 2009; DOI: 10.1158/0008-5472.CAN-08-3860

Downloaded from cancerres.aacrjournals.org on April 14, 2017. © 2009 American Association for Cancer Research.
To identify protein cargo in SV in an unbiased manner, LNCaP/LacZ and LNCaP/MyrAkt1 SV protein was fractionated by SDS-PAGE. Two prominent zones containing the most abundant proteins ran at approximately 80 and 30 kDa (Supplementary Fig. 52B). These zones were excised and analyzed by tandem mass spectrometry. Each protein was identified from at least two unique peptides with an ion score of no less than 40 (P < 0.01). SV proteins were sorted according to their MOWSE scores and semiquantified using spectral counting (15). Numerous signaling proteins involved in cell metabolism, mRNA processing, and cell growth and motility were identified (Supplementary Table S1; Fig. 3A). The majority of SV proteins were present in both sublines, although as shown, there were some quantitative differences (only proteins with <15 spectral counts in at least one sample are shown). This result suggests the possibility of changes in SV protein composition with alterations in signal transduction (e.g., up-regulation Akt signaling in LNCaP/MyrAkt1 cells). Multiple proteins of potential relevance to cancer progression were found, including the following: (a) the cancer cell–specific isoform of pyruvate kinase M2 (PKM2), a phosphotyrosine-binding protein that promotes increased cell growth and tumor development (28); (b) programmed cell death 6 interacting protein (PDCD6IP), also known as Alix, recently shown to inhibit apoptosis (29); (c) poly(A)-binding protein 1 (PABPC1), which associates with paxillin and promotes cell migration; and (d) hnRNPK, a multifunctional regulator of transcription and translation induced by extracellular growth promoting signals that enhance cancer cell proliferation (30).

Mass spectrometry data were analyzed using the MetaCore data mining tool10 to determine whether bleb/SV cargo could be organized into coherent networks and linked to one or more biological processes. Three statistically significant associations with GeneGo ontology pathway or biological process models, all related to mRNA translation, were identified using SV proteins from LNCaP/LacZ cells (Table 1). Interestingly, a much greater number of significant associations was detected using SV cargo from LNCaP/MyrAkt1 cells (nine such associations with LNCaP/Akt1 cells versus three seen with LNCaP/LacZ cells), including links to cytoskeletal rearrangement, cell cycle progression, inflammation, DNA damage, cell adhesion, and mRNA translation. These data suggest the possibility that the vesicles originating from plasma membrane blebs might be able to relay signals across cell boundaries in a manner similar to recently described glioblastoma-derived oncosomes (8).

**Horizontal signaling.** Because analysis of LNCaP SV cargo suggested that the bleb-derived material might possess bioactivities described for oncosomes, we asked whether LNCaP/MyrAkt1 SV are capable of altering signal transduction in recipient cells in a horizontal fashion. SV were isolated from LNCaP/MyrAkt1 cells and recovered material was quantified by determining protein content. Recipient LacZ cells exposed to SV from LNCaP/MyrAkt1 cells showed a time-dependent activation of the Akt pathway (Fig. 3B), as assessed using a consensus Akt-phosphorylated substrate antibody (31). Consistent with this, levels of active Akt1 (p-S473) and its phosphorylated targets GSK3α/β (p-S21/9) and FoxO1 (p-S256) increased in a time-dependent manner. In these

### Table 1. Proteins identified by mass spectrometry were analyzed by MetaCore software (GeneGo, Inc.) using two algorithms in which the output is either an intracellular signaling pathway or a biological process

<table>
<thead>
<tr>
<th>Pathway models</th>
<th>LacZ (-log P)</th>
<th>MyrAkt1(-logP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Translation: elongation: termination</td>
<td>3.9</td>
<td>(N/s)</td>
</tr>
<tr>
<td>Cytoskeleton: regulation of cytoskeleton rearrangement</td>
<td>(N/s)</td>
<td>4.7</td>
</tr>
<tr>
<td>Cell cycle: meiosis</td>
<td>(N/s)</td>
<td>5.9</td>
</tr>
<tr>
<td>Cytoskeleton: cytoplasm microtubules</td>
<td>(N/s)</td>
<td>(N/s)</td>
</tr>
<tr>
<td>Inflammation: IL-6 signaling</td>
<td>(N/s)</td>
<td>4.1</td>
</tr>
<tr>
<td>DNA damage: check point</td>
<td>(N/s)</td>
<td>4.1</td>
</tr>
<tr>
<td>Inflammation: TREMI signaling</td>
<td>(N/s)</td>
<td>3.9</td>
</tr>
<tr>
<td>Cell cycle: GI-S</td>
<td>(N/s)</td>
<td>3.6</td>
</tr>
<tr>
<td>Cell adhesion: cell junctions</td>
<td>(N/s)</td>
<td>3.6</td>
</tr>
<tr>
<td>Transduction: translation initiation</td>
<td>4.5</td>
<td>(N/s)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biological process models</th>
<th>LacZ (-log P)</th>
<th>MyrAkt1(-logP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycolysis and gluconeogenesis</td>
<td>(N/s)</td>
<td>(N/s)</td>
</tr>
<tr>
<td>Vitamin K metabolism</td>
<td>(N/s)</td>
<td>(N/s)</td>
</tr>
<tr>
<td>Transcription: role of heterochromatin protein(HPI) family in transcriptional silencing</td>
<td>(N/s)</td>
<td>1.5</td>
</tr>
<tr>
<td>Cell cycle: role of 14-3-3 proteins in cell cycle regulation</td>
<td>(N/s)</td>
<td>5.7</td>
</tr>
<tr>
<td>Translation: regulation of translation initiation</td>
<td>1.6</td>
<td>(N/s)</td>
</tr>
<tr>
<td>Cytoskeleton remodeling: neurofilament</td>
<td>(N/s)</td>
<td>(N/s)</td>
</tr>
<tr>
<td>Glycolysis and gluconeogenesis</td>
<td>(N/s)</td>
<td>(N/s)</td>
</tr>
<tr>
<td>Transcription: Role of AP in regulation of cellular metabolism</td>
<td>(N/s)</td>
<td>(N/s)</td>
</tr>
<tr>
<td>Cell cycle: spindle assembly and chromosome separation</td>
<td>(N/s)</td>
<td>(N/s)</td>
</tr>
<tr>
<td>Development: role of CDKS in neuronal development</td>
<td>(N/s)</td>
<td>(N/s)</td>
</tr>
</tbody>
</table>

**NOTE:** Significance was defined as P value of <0.05. Abbreviation: N/s, not significant.
experiments, HA-tagged MyrAkt1 was transferred to recipient cells (Fig. 3B, arrow). This finding shows that vesicles shed by LNCaP/MyrAkt1 cells possess activities associated with oncosomes. They also show that an oncoprotein (MyrAkt1) can be transferred across cell boundaries with SV as a vehicle. Consistent with these data, LNCaP/MyrAkt1 SV also evoked robust p-Tyr signaling and EGFR pathway activation in recipient cells (Fig. 3C). SV material also elicited increased levels of vimentin mRNA in WPMY-1 prostate stromal cells (Fig. 3D), suggesting that the vesicles are capable of evoking a stromal reaction (32).

The actin-nucleating protein DRF3/Dia2 inhibits bleb formation. Nonapoptotic membrane blebbing arises from membrane deformations resulting from actomyosin contraction (4) and has been linked to amoeboid cell motility and matrix invasion (23). These findings imply that actin remodeling may affect oncosome formation. To test this idea, we focused on Diaphanous-Related Formin 3 (DRF3), the human homologue of the mouse actin nucleating protein Drf3/mDia2 (33). DRF3 is encoded on chromosome 13q, which contains a region of genomic instability in PCa (34). An inhibitor of Drf3 was recently reported to induce

Figure 4. DRF3 knockdown by RNAi results in oncosome secretion. A, verification of DIAPH3 gene silencing by siDRF3 in DU145 cells by Western blot (top) and RT-PCR (bottom). Control nontargeting siRNA was a negative control. B, FITC-CTxB staining of DU145 cells showing blebbing in siDRF3-transfected or siRNA control cells, with or without EGF (3 h; right). C, quantitative analysis of bleb formation in DU145 cells treated with siRNA for DRF3 or control siRNA, ± EGF. D, proliferation assay (left) and migration assay (right) in DU145 cells treated with SV prepared from DU145 cells treated with siRNA control oligos, ± EGF, or with DRF3-targeted oligos. *, P < 0.05.
nonapoptotic blebbing (35), suggesting the possibility that DRF3 may oppose blebbing.

DRF3 knockdown by RNA interference (RNAi), using a pool of four siRNA oligos targeted to DRF3, dramatically increased bleb formation in the presence of EGF (Fig. 4A–C), a result that implicates cytoskeletal dynamics in the blebbing process. To determine whether SV derived from cells in which DRF3 had been knocked down would affect cell behavior in recipient cells, we did proliferation and migration assays using DU145 cells exposed to SV derived from DU145 cells in which DRF3 expression was reduced by RNAi. Cell proliferation and migration were increased in recipient cells exposed to SV isolated from DU145 cells treated with DRF3 siRNA, at a level quantitatively comparable with that elicited in donor cells by activation of EGFR alone (Fig. 4D).

**Discussion**

In this study, we describe the production of nonapoptotic membrane blebs in human PCa cells in response to activation of oncogenic signaling (EGFR and Akt activation). Formation of these dynamic structures correlates with cell migration and, when shed from tumor cells, they elicit biological responses in recipient cells in a manner that resembles—but is mechanistically distinct from—paracrine signaling. We conclude that the microvesicles we have studied here are functionally equivalent to the bioactive oncosomes recently described as products of aggressive glioblastoma cells (8). We also identify the actin nucleating protein DRF3 as an endogenous inhibitor of oncosome formation. Analysis of primary and metastatic prostate tumors using high-density SNP arrays and FISH resulted in a highly significant association between chromosomal loss at the DRF3 (DIAPH3) locus and metastatic disease. To our knowledge, this is the first study that describes oncosome formation by PCa cells, the first to link formation of SV with nonapoptotic blebbing, and the first to provide evidence for involvement of the formin DRF3 in metastases in any tumor system. Oncosome activity was shown in two unrelated PCa cell line backgrounds, LNCaP and DU145, and similar membrane blebbing was evoked in PC-3 cells in response to EGF, suggesting that this is a general phenomenon. The precise relationship between the surprisingly large (0.5–5 μm) SV we have observed here by fluorescence microscopy, using several membrane probes, and the smaller (-0.1–1 μm) secreted vesicles reported by other groups (36, 37) remains to be determined.

The results of unbiased mass spectrometry studies, analysis of known proteins, and bioinformatics evaluation of SV cargo proteins are consistent with the finding that oncosome formation can result in transfer of membrane-associated protein complexes within the tumor microenvironment. Oncosomes might also be vectors of certain cancer progression markers that are detectable in the circulation. One such marker, Cav-1, identified in our study as oncosome cargo, is a circulating biomarker of metastatic PCa (13, 27, 38). Our data suggest that oncosome secretion is a mechanism whereby the integral membrane protein Cav-1 obtains access to the extracellular space, where it then becomes available.

**Frequent chromosomal deletions at the DIAPH3 locus in metastatic PCAs.** The above findings suggest that DRF3 is capable of inhibiting the blebbing/amoeboid phenotype. To determine the potential relevance of these observations to human PCAs, we evaluated the human DRF3 locus (DIAPH3) for chromosomal alterations using 100K SNP arrays, profiling 12 primary PCa tumors and 27 metastatic tumors. A total of 19 (49%) of these tumors exhibited deletions at the DIAPH3 locus (Fig. 5A), much higher than the overall 20% rate of deletion across the genome. Although all of these tumors, including the primaries, were sufficiently enriched to observe copy-number changes elsewhere in the genome, at the DIAPH3 locus, deletions were observed more frequently among metastases [18 of 27 (67%)] than primaries [1 of 12 (8.3%); 2-sided Fisher’s exact test, \( P = 0.001 \)]. In a different cohort of patient samples, FISH, an alternative method, was used to assess the DIAPH3 locus for chromosomal alterations. FISH results indicated chromosomal loss of DIAPH3 in 7 of 35 (20%) primaries, and 9 of 14 (64%) metastases (Fig. 5B), confirming a significantly higher frequency of deletions in aggressive disease in comparison with primary tumors (2-sided Fisher’s exact test, \( P = 0.006 \)). DIAPH3 deletion was not detected in benign tissues.

**Figure 5.** Genomic profiling of primary and metastatic PCas at the DIAPH3 locus. A, amplifications (red) and deletions (blue), determined by segmentation analysis of normalized signal intensities from 100K SNP arrays (see Materials and Methods), are displayed for 39 PCas (X-axis; primaries and metastases are designated along the top) for the q arm of chromosome 13 (chromosomal positions indicated along the Y-axis include the centromere, q-terminus, and RB1 loci). B, DIAPH3 fluorescent in situ hybridization was done by dual color FISH on PCa tissues. Left, FISH image shows both red signals (DIAPH3 locus on chr13q21.2) and green signals (a stable region on chr21q22.12) in representative nuclei indicating no deletion of DIAPH3 in tumor cells. Right, FISH image shows one red signal (DIAPH3 locus on chr13q21.2) and two green signals (a stable region on chr21q22.12) in representative nuclei. Loss of the second red signal is consistent with deletion at DIAPH3. Original magnification of FISH images, ×60 objective.
to act at distant sites. Another SV cargo protein identified by mass spectrometry is hnRNP-K, which we recently showed to be a novel Akt binding protein and regulator of androgen receptor translation (39). mRNA translation was repeatedly identified in the present study using the MetaCore software tool as a biological process that was significantly associated with bleb cargo proteins.

Our data indicate that the actin nucleator DRF3 is capable of inhibiting oncosome formation, because DRF3 knockdown by RNAi increased blebbing in DU145 cells, particularly in the presence of EGF. DRF3 is expressed by LNCaP, DU145, and PC-3 human prostate cell lines (data not shown). Formin homology proteins mediate cytoskeletal dynamics (9, 35) and, as a group, have been implicated in a wide range of cellular functions, including motility and vesicular trafficking (40, 41). The formin FHOD1, which exhibits 45% sequence homology to DRF3, was recently implicated in Src-dependent plasma membrane blebbing (42). Human DRF3 is not well-studied, although analyses of the mouse homologue Drf3, and the close mouse paralog, Drf1/mDia1, indicate that DRF3 likely plays a role within a critical signaling node that controls the amoeboid form of cell movement (45) and our data indicate that membrane blebs can either dissociate from the cell or be retracted in an actin-dependent manner (4). Blebbing has been linked to the amoeboid form of cell movement (45) and our data indicate that DRF3 likely plays a role within a critical signaling node that controls the amoeboid phenotype. The finding that DRF3 silencing in SV donor cells resulted in increased cell proliferation and migration in SV recipient cells provides an important new link between (a) blebbing and the amoeboid phenotype and (b) the production of vesicles that can propagate signals horizontally in the tumor microenvironment. These experimental data are consistent with our analysis of human prostate tumors, indicating that chromosomal loss at the DRF3 coding region is associated with metastatic disease. Loss of function at the DIAPH3 locus from somatic mutation may lead to alterations in the propensity toward invasion or metastasis. We are currently testing this hypothesis experimentally.

Our experiments suggest that oncosome transfer between tumor cells, or between tumor and stroma, could play a role in propagation of aggressive behavior within the tumor microenvironment. As pointed out by Al-Nedawi and colleagues (8), oncosome exchange is markedly different from paracrine effects induced by soluble ligands. However, this process could result in paracrine pathways through intercellular sharing of membrane-associated signaling complexes. Although our study focuses on PCa, a similar microvesicular transfer mechanism may operate in other tumor systems.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 10/3/08; revised 4/1/09; accepted 4/27/09; published OnlineFirst 6/23/09.

Grant support: National Institutes of Diabetes, Digestive and Kidney Diseases R37T7556, P50 DK62998, National Cancer Institute (NCI) B101 CA112301 and DAM17-03-2-0003 (M.R. Freeman), NCI K99 CA131472 (D. Vi Zoo), DOD PCRP W81XWH-07-1-0188 (M.H. Hager), W81XWH-08-1-0139 (W. Yang), the AUA Foundation/GlaxoSmithKline (M.H. Hager), the Pacific Northwest Prostate Cancer Specialized Programs of Research Excellence CA97186, NCI P01CA085897 (L. True), K08CA122933 (R. Beroukhim), and B01CA116337-01A1 (M.A. Rubin and F. Demichelis). J. Kim is a Fishbein/ICA Scholar and a New York Academy of Medicine Edwin Beer Scholar.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. H. Steen for assistance with mass spectrometry and Paul Guthrie for technical assistance.

References


29. Fishbein/ICA Scholar and a New York Academy of Medicine Edwin Beer Scholar. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. H. Steen for assistance with mass spectrometry and Paul Guthrie for technical assistance.
Oncosome Formation in Prostate Cancer: Association with a Region of Frequent Chromosomal Deletion in Metastatic Disease

Dolores Di Vizio, Jayoung Kim, Martin H. Hager, et al.


Updated version
Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-08-3860

Supplementary Material
Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2009/07/21/0008-5472.CAN-08-3860.DC1

Cited articles
This article cites 44 articles, 22 of which you can access for free at: http://cancerres.aacrjournals.org/content/69/13/5601.full.html#ref-list-1

Citing articles
This article has been cited by 19 HighWire-hosted articles. Access the articles at: /content/69/13/5601.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.